Science News – February 10, 2026
Data from Finnish and Swedish cohorts link specific RAS mutation subtypes to distinct treatment outcomes, strengthening the evidence base for biomarker‑guided therapy.
Legal Advice article – February 10, 2026
On 9 February 2026, Novo Nordisk announced it has filed a lawsuit against U.S. telehealth company Hims & Hers, alleging that the firm is offering compounded, non‑FDA‑approved versions of Wegovy and Ozempic that could put patients at risk.
Acquisition – February 9, 2026
Orna is advancing a new class of therapeutics utilizing engineered circular RNA paired with novel lipid nanoparticles to allow the patient’s own body to generate cell therapies that can treat underlying disease.
Global report – February 9, 2026
Innovent Biologics has announced a strategic collaboration with Eli Lilly and Company (“Lilly”) to advance novel medicines in oncology and immunology.
Science News – February 9, 2026
A 2026 population‑based cohort study covering Denmark, Finland, Iceland, Norway and Sweden analysed 1‑year relative survival and excess mortality in cancer patients diagnosed during March–December 2020 versus expectations from 2011–2019.
Biotech Business – February 9, 2026
Medivir has completed a directed share issue of SEK 45 million (before issue costs) to Carl Bennet AB, issuing 90 million new shares at SEK 0.50 per share—a 19 percent premium to the closing price on February 5, 2026.
Opinion & debate
Clinical Trials – February 2, 2026
SynAct Pharma has initiated a Phase 2 study (RESPIRE) with resomelagon in patients hospitalized with respiratory insufficiency due to viral infections.
Clinical Trials – January 27, 2026
The results showed that approximately 30 percent of patients achieved complete skin clearance (PASI 100) at week 16, and that more than half reached almost complete clearance (PASI 90).
Clinical Trials – January 27, 2026
The results show that all patients responded positively to the ODX treatment, with a transition from progressive disease to stable disease.
Clinical Trials – January 12, 2026
Elicera Therapeutics has announced final data from its Phase I/IIa clinical trial evaluating the oncolytic virus ELC-100 in patients with advanced, end-stage neuroendocrine tumors who had exhausted all currently available therapeutic options and having progressing diseases.
Clinical Trials – January 9, 2026
Sobi has announced that topline results from the Phase 2a EMBRACE study evaluating Gamifant (emapalumab) for interferon-gamma (IFNγ)-driven sepsis (IDS), showed proof-of-concept with observed improvement in organ dysfunction and survival.
Clinical Trials – January 8, 2026
Phase 1b biomarker data show clear evidence of biological response to HER-096 in people with Parkinson’s disease, states the company.
Stryker
Looking for a place that values your unique talents? Discover Stryker’s award-winning culture.
Confidential
PharmaRelations, together with the Board of Directors, are seeking an experienced and visionary CEO to lead a rapidly growing Life Science company through its next phase of development and growth. The company is based in southern Sweden.
Stryker
Looking for a place that values your unique talents? Discover Stryker’s award-winning culture.
GEA Process Engineering
GEA – “Engineering for a better world”. GEA, one of the world’s largest systems suppliers for the Food, Beverage, and Pharmaceutical sectors.
PharmaRelations
This is a leadership position that combines strategic oversight, business development, and team leadership. The successful candidate will play a pivotal role in shaping our pharmacovigilance and safety functions across both clinical and post-marketing environments.
dsm-firmenich
dsm-firmenich is your innovation partner in all things: nutrition, health and beauty.
In a new job – January 29, 2026
After close to ten years as CEO, Annette Säfholm has decided to step down from her role. The Board of Directors has appointed Julie Waras Brogren as the new Chief Executive Officer.
In a new job – January 28, 2026
“Claus has a strong track record of building and scaling health-focused businesses, combining strategic clarity with deep customer and market insight. His experience across regulated health products, international commercialization, and partnership-driven growth makes him exceptionally well suited to lead Sigrid into its next phase. I would also like to thank Sana Alajmovic for building the […]
In a new job – January 23, 2026
The company is in an intensive development phase in which several vaccine candidates are being advanced in parallel towards clinical development. To ensure continued high execution capacity and long-term competence, the company is now strengthening its organisation through recruitment.
Careers article – February 3, 2026
At Elekta’s Strategic Update for investors the company announced that, as a consequence of the company’s new operating model, it is reducing the number of employees by 450.
Careers article – January 15, 2026
A large international study published in The Lancet, suggests that adding just five minutes of moderate-intensity activity per day – or cutting sitting time by 30 minutes – could prevent a substantial share of premature deaths.
Careers article – January 12, 2026
When working, many of us sit for long periods of time, especially at desks and in front of screens.
Profiles in Business – December 8, 2025
Successful businessman and former chairman of AstraZeneca, Leif Johansson, has accumulated vast experience and knowledge about international competition, leadership, business development, and entrepreneurship, not least when it comes to science-driven industries like the life science industry.
Nobel Prize 2025 – November 25, 2025
With a family legacy in medicine dating back to the Shogun era, the Japanese immunologist Dr. Shimon Sakaguchi has dedicated his career to the science. A 30-year-old pivotal discovery led him to this year’s Nobel Prize in Physiology or Medicine for research in peripheral immune tolerance.
Nobel Prize 2025 – November 25, 2025
Nobel Prize laureate Mary E. Brunkow’s career path has shifted between industry and academia but her end goal to generate clinical benefit and her passion for exploring new areas have never wavered.

Biotech Business – February 4, 2026
Cereno Scientific is broadening the development focus of its HDAC inhibitor CS014 to pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Agreement – January 30, 2026
Bavarian Nordic has announced an agreement with Eurofarma, granting them exclusive rights to sell and distribute Bavarian Nordic’s chikungunya vaccine, CHIKV VLP, in Brazil.
Global report – January 30, 2026
AstraZeneca has entered a new strategic collaboration agreement with CSPC Pharmaceuticals to advance the development of multiple next-generation therapies for obesity and type 2 diabetes across eight programmes.
MedTech Business – February 3, 2026
On 10 December 2025, Amplex announced a public offer to the holders of shares and warrants of ADDvise Group. On 27 January 2026, Amplex announced that the offer had been accepted to such extent that Amplex will become the owner of 94.31 per cent of all shares in ADDvise upon settlement of the offer.
Acquisition – February 3, 2026
Nanologica has acquired Ardena Södertälje AB, the API CDMO in Södertälje, from Ardena Sweden in an all‑share deal valued at approximately SEK 8.6 million.
Agreement – January 20, 2026
The two companies have entered into an agreement regarding the use of the OnDosis drug delivery platform, the Dosage Manager, in Diamond’s psychoactive low-dose psilocybin programs.
Biotech article – February 5, 2026
Denmark’s recent regulatory moves are increasingly described as a competitive advantage for the country’s life science sector, as the government aligns national rules with the EU Pharmaceutical Package and the forthcoming Biotech Act, according to analysis from Pharmadanmark and EU policy commentators.
Biotech Business – February 4, 2026
The company is initiating additional preclinical studies within its influenza program, with a focus on pandemic avian influenza.
Biotech Business – February 2, 2026
Alvotech has entered into supply and commercialization agreements with Sandoz covering multiple biosimilar candidates in Canada, and in Australia and New Zealand.
Science News – February 4, 2026
A Swedish–Norwegian research team has identified blood-based biomarkers that could flag Parkinson’s disease up to two decades before classic motor symptoms appear.
Science News – February 4, 2026
Researchers at the University of Gothenburg have developed a new class of boron–fluorine compounds that could make late‑stage optimisation of drugs and imaging agents both simpler and more sustainable. The work, published in Angewandte Chemie, introduces stable “BF₂‑boracycles” that can be made metal‑free, at scale, and without time‑consuming purification – yet remain highly reactive in […]
Science News – February 3, 2026
Google DeepMind has introduced AlphaGenome, a large deep learning model that predicts how changes in noncoding DNA affect gene regulation, aiming to unlock the “dark genome” for disease research and drug discovery (Agarwal et al., Nature, 2026).
Upcoming events
This site uses cookies